Gene · 4277
Papers3,381
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
941 to 960 of 3,381
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells. | mBio | 2021 | 34781735 | PubTator, text mining | PubMed |
| Making a Killer: Selecting the Optimal Natural Killer Cells for Improved Immunotherapies. | Front Immunol | 2021 | 34777383 | PubTator, text mining | PubMed |
| Gamma Delta T Cells and Their Involvement in COVID-19 Virus Infections. | Front Immunol | 2021 | 34777353 | PubTator, text mining | PubMed |
| Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets. | Int J Mol Sci | 2021 | 34769131 | PubTator, text mining | PubMed |
| Epigenetic Dysregulations in Merkel Cell Polyomavirus-Driven Merkel Cell Carcinoma. | Int J Mol Sci | 2021 | 34768895 | PubTator, text mining | PubMed |
| Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity. | J Clin Med | 2021 | 34768683 | PubTator, text mining | PubMed |
| NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. | Front Oncol | 2021 | 34765554 | PubTator, text mining | PubMed |
| Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies. | Immunotargets Ther | 2021 | 34754837 | PubTator, text mining | PubMed |
| Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. | Ann Transl Med | 2021 | 34734027 | PubTator, text mining | PubMed |
| Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma. | BMC Gastroenterol | 2021 | 34724892 | PubTator, text mining | PubMed |
| Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls. | Front Med (Lausanne) | 2021 | 34722568 | PubTator, text mining | PubMed |
| Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies. | Front Oncol | 2021 | 34722319 | PubTator, text mining | PubMed |
| The HHV-6A Proteins U20 and U21 Target NKG2D Ligands to Escape Immune Recognition. | Front Immunol | 2021 | 34721381 | PubTator, text mining | PubMed |
| NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma. | Front Oncol | 2021 | 34712615 | PubTator, text mining | PubMed |
| Blocking of EphA2 on Endometrial Tumor Cells Reduces Susceptibility to Vδ1 Gamma-Delta T-Cell-Mediated Killing. | Front Immunol | 2021 | 34691070 | PubTator, text mining | PubMed |
| 'Off-the-Shelf' Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells. | Cells | 2021 | 34685611 | PubTator, text mining | PubMed |
| Single-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCT. | J Clin Med | 2021 | 34682758 | PubTator, text mining | PubMed |
| Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications. | Int J Mol Sci | 2021 | 34681626 | PubTator, text mining | PubMed |
| Epstein-Barr Virus-Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies. | Cancers (Basel) | 2021 | 34680337 | PubTator, text mining | PubMed |
| Genomic Risk Factors for Cervical Cancer. | Cancers (Basel) | 2021 | 34680286 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4277/papers?page=48